“…The ultimate goal of these investigations was to obtain antibodies of sufficient specificity to obviate the necessity of extracting chlordiazepoxide from plasma for its determination. Thus, the antibodies would have to be specific for chlordiazepoxide in the presence of all of its known plasma metabolites in humans, namely N-desmethylchlordiazepoxide (4), demoxepam (5), and N-desmethyldiazepam (9). Therefore, the antibodies would be required to distinguish structural changes occurring only in the 1,4-diazepine ring or "fingerprint" region.…”